Scientific Review: latest discoveries in precision oncology

In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked four articles that provide valuable insights into the world of oncology.

Zenocutuzumab Earns FDA Priority Review for NRG1+ NSCLC and Pancreatic Cancer

Zenocutuzumab, a bispecific antibody, has received FDA priority review for NRG1 fusion-positive non-small cell lung cancer (NSCLC) and pancreatic cancer. This decision is based on promising phase 1/2 eNRGy trial data. Learn more about this significant development.
Read the article

FDA oncologydrug decisions coming soon

In June 2024, the FDA will decide on tarlatamab for advanced small-cell lung cancer (SCLC) and imetelstat for lower-risk myelodysplastic syndromes (MDS). Early trials show promising results for both therapies, which could significantly impact treatment options.
Read the article

New treatments for Non-Small Cell Lung Cancer (NSCLC)

This article provides a comprehensive review of current first-line treatments for non-small cell lung cancer (NSCLC) without oncogenic alterations, focusing on immune checkpoint inhibitors (ICIs), combination treatments, and emerging therapies. It discusses strategies for PD-L1 high expressers, dual checkpoint blockade, and future approaches like antibody-drug conjugates.
Read the article

FDA-Approved AI Algorithm Reveals Bias in Mammogram Screening

A study found that an FDA-approved AI algorithm used in mammogram screenings shows higher false positive rates for African-American and older women compared to White and younger patients. This discrepancy highlights the need for more diverse training datasets to ensure AI tools are effective across all demographics.
Read the article

You may also be interested in these resources

Scientific Application Note

Endometrial Cancer Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002)

Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P),...

Read more →
logo primaire 2019 06 (white)

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases.

Company

OncoDNA S.A. (headquarters)
Rue Louis Breguet 1
BE-6041 Gosselies

+32 (0) 71 18 35 00

Links

Support

©OncoDNA 2024. All rights reserved. VAT:BE0501631837
Made by Créatonit   Sitemap
Share This